Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Jeffrey Smith, MD FRCP
Alder Biopharmaceuticals, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
31 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- St. Vincent'S Hospital
Darlinghurst, New South Wales, Australia
- Calvary Mater Newcastle
Waratah, New South Wales, Australia
- Royale Brisbane and Women'S Hospital
Herston, Queensland, Australia
- Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
- Adelaide Radiotherapy Centre
Adelaide, South Australia, Australia
- Royal Adelaide Hospital
Adelaide, South Australia, Australia
- Lkh Graz, Hno Ambulanz
Graz, Austria
- Univ. Klinik Fur Innere Medizin Iii
Salzburg, Austria
- Hanusch Krankenhaus
Vienna, Austria
- Cancer Centre of Southeastern Ontario
Kingston, Ontario, Canada
- Maisonneuve-Rosemont Hospital
Montreal, Quebec, Canada
- Chuq-L'Hotel-Dieu de Quebec
Québec, Canada
- Uniklinik Koln
Cologne, Germany
- Universitatsklinikum Freiburg
Freiburg im Breisgau, Germany
- University Medical School, Saarland
Homburg, Germany
- A.O. San Paolo - Polo Universitario
Milan, Italy
- Istituto Nazionale Dei Tumari
Milan, Italy
- Azienda Ospedaliero-Universitaria Santa Maria Della Misericordia
Udine, Italy
- Morton Plant Mease Health Care
Clearwater, Florida, United States
- Dana Farber Cancer Institute
Boston, Massachusetts, United States
- Karmanos Cancer Center
Detroit, Michigan, United States
- Detroit Clinical Research Center
Farmington Hills, Michigan, United States
- John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, United States
- University of New Mexico Cancer Center
Albuquerque, New Mexico, United States
- Mount Sinai School of Medicine
New York, New York, United States
- Suny Upstate Medical University
Syracuse, New York, United States
- Temple University Hospital
Philadelphia, Pennsylvania, United States
- Spartanburg Regional Medical Center
Spartanburg, South Carolina, United States
- Cancer Specialists of Southern Texas
Corpus Christi, Texas, United States
- University of Texas Southwestern Medical Center
Dallas, Texas, United States
- Va Puget Sound Health Care Syatem
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jul 2011
- Primary completion
- 30 Apr 2013
- Completion
- 31 Mar 2014
- Last update posted
- 11 May 2021
- Registered enrollment
- 76
- Registry id
- NCT01403064
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.